USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Biomarine Technologies, Inc.
Address:
4459 A 134th Place
Tukwila, WA 98168
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $300,000.00 5
SBIR Phase II $939,000.00 2

Award List:

EICOSAPENTAENOIC ACID:ALGAE CULTURE & EXTRACTION

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Rodner R Winget
Abstract:
N/a

EICOSAPENTAENOIC ACID:ALGAE CULTURE & EXTRACTION

Award Year / Program / Phase:
1990 / SBIR / Phase II
Award Amount:
$439,000.00
Agency:
HHS
Principal Investigator:
Rodner R Winget
Abstract:
Biomarine technologies, inc., is in the business of developing high-value chemicals from cultured microalgae. the products in this project are three forms of eicosapentaenoic acid (epa), an essential fatty acid with therapeutic and prophylactic applications for cardiovascularpatients. the goal is to… More

EICOSAPENTAENOIC ACID FOR TOPICAL SKIN DISEASE TREATMENT

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Winget, Rodner R , Principal Investigator
Abstract:
N/a

EICOSAPENTAENOIC ACID FOR TOPICAL SKIN DISEASE TREATMENT

Award Year / Program / Phase:
1992 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Winget, Rodner R , Principal Investigator
Abstract:
The long term goal of this project is to provide an active ingredient for topical treatment of skin diseases, especially psoriasis, acne, eczema, and atopic dermatitis. the specific aim is to (1) develop the chemistry for isolating a species of lipid from marine algae that contain high… More

Eicosapentanoic Acid for Topical Skin Cancer Treatment

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Rodner R. Winget
Abstract:
The long term goal is to develop topical therapy for cancer with eicosapentaenoic acid (EPA), which has been shown to have anti-inflammatory and anti-tumorigenic properties. EPA has no known side effects other than a mild increase in bleeding time. This project will develop the technology for… More

Algal EPA Aerosol to Inhibit Bronchial Inflammation

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Rodner R. Winget
Abstract:
The long term goal of this research is to develop topical anti-inflammatory therapy for asthma with eicosapentaenoic acid (EPA) extracted from marine algae. EPA has no known side effects other than a mild increase in bleeding time. This project will develop the technology for purifying a particular… More

Bioadhesive Delivery for Algal Eicosapentaenoic Acid

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Rodner Winget
Abstract:
We will develop a new therapy for esophagitis with eicosapentaenoic acid (EPA) compounds extractedmarine algal. EPA has no known side effects other than mild increase in bleeding time when used systmarine algal EPA will be a significant contribution to existing clinical practice. This Phase I… More